Back to company

XGX Pharma ApS: Financial statements 2015

CVR: 32289290

XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK -32,643 and a net result of DKK -34,858 compared with DKK -14,436 the year before. Equity amounted to DKK -179,722.

Gross Profit
-32,643 kr.
Profit/Loss
-34,858 kr.
Equity
-179,722 kr.
Total Assets
900,385 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015--33 t.-35 t.-180 t.-
2014---14 t.-145 t.-
2013-145 t.145 t.130 t.-
2012-84 t.96 t.-14 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2015

XGX Pharma ApS: The 2014 annual report is outJun 26, 2015

XGX Pharma ApS has published its annual report for 2014. The net result was DKK -14,436.

Auditor steps down at XGX Pharma ApSJun 23, 2015

As of June 23, 2015, REVISIONSFIRMAET WOIREMOSE & PARTNER REGISTRERET REVISIONSANPARTSSELSKAB has stepped down as auditor of XGX Pharma ApS.

XGX Pharma ApS appoints new auditorMay 15, 2015

As of May 15, 2015, REVISIONSFIRMAET WOIREMOSE & PARTNER REGISTRERET REVISIONSANPARTSSELSKAB has been appointed auditor of XGX Pharma ApS.

Auditor steps down at XGX Pharma ApSMay 15, 2015

As of May 15, 2015, Kreston CM Statsautoriseret Revisions interessentskab has stepped down as auditor of XGX Pharma ApS.

About XGX Pharma ApS

XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The company is owned by Unimedic Pharma AB. The company has 2 employees. In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity amounted to DKK 30,787,180.